HomeTrialNCT06244082
🔬NCT06244082Phase 2ACTIVE NOT RECRUITING

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping

Study Summary

AOC 1044-CS2 (EXPLORE44-OLE) is an Open-label Study to Evaluate the Long-Term Safety and Tolerability of AOC 1044 Administered Intravenously to DMD Participants with Mutations Amenable to Exon 44 Skipping.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment39 participants
Primary Completion
Lead SponsorAvidity Biosciences, Inc.
Data Retrieved2026-04-11 04:26:08.607587+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.